Tag: Sublocade

Sublocade, a buprenorphine injection, has a boxed warning from the FDA due to the risk of serious harm or death if administered intravenously [1.3.1, 1.3.2, 1.3.3]. So, what happens if Sublocade is injected wrong, and why are the consequences so severe?

According to the FDA, certain opioids, including buprenorphine (the active ingredient in Sublocade), have been associated with serotonin syndrome, a potentially dangerous condition. This means that for individuals using Sublocade, there is a risk, particularly when combined with other medications that affect serotonin levels.

Roughly 3 million American citizens have an active opioid use disorder (OUD). For individuals exploring medication-assisted treatment (MAT) options, the question 'is sublocade better than vivitrol?' is a common consideration, though the answer is not a simple yes or no and depends heavily on individual circumstances.

Sublocade is a medication that delivers buprenorphine over an extended period, and in a 12-week study, a 300mg dose was shown to block the drug-liking effects of potent opioids like hydromorphone. This once-monthly injection contains buprenorphine, a partial opioid agonist that binds to and partially activates the brain's opioid receptors, effectively blocking other, full-agonist opioids from producing their euphoric effects. Understanding how **does Sublocade block other drugs?** is crucial for patients, families, and healthcare providers involved in the treatment of opioid use disorder (OUD).

In 2022, an estimated 9.37 million U.S. adults needed treatment for Opioid Use Disorder (OUD), but only 25.1% received recommended medications [1.10.1]. Understanding what Sublocade does to the brain is key to seeing its role in addressing this treatment gap by stabilizing brain chemistry [1.2.5].

According to the Substance Abuse and Mental Health Services Administration (SAMHSA), Medication-Assisted Treatment (MAT) has been shown to significantly reduce opioid-related overdose deaths. For many patients, a critical question arises: Is sublocade safer than Suboxone? The answer depends on a careful comparison of their unique safety features and how they align with individual needs.

Currently, there is no generic version of the extended-release buprenorphine injection, Brixadi, available in the United States. Understanding the availability and costs associated with brand-name medications is crucial for patients managing opioid use disorder, as alternatives exist that may offer similar therapeutic benefits at a different price point.

While Sublocade is a proven treatment for opioid use disorder, like any medication, it comes with a range of potential side effects, especially with long-term use. Patients considering or undergoing treatment must understand **what are the long-term side effects of sublocade** to manage their recovery journey effectively and make informed decisions with their healthcare provider.

In a 24-week clinical study, 30% of participants receiving Sublocade abstained from other opioids for at least 80% of the study's duration [1.6.5]. As a treatment for Opioid Use Disorder (OUD), a key question for many is: **Is Sublocade long acting?** The answer is yes; it's designed as a once-monthly injection [1.3.1].

In 2018, an estimated 10.3 million people aged 12 or older misused opioids [1.4.4]. While Sublocade is a key treatment, it's vital to ask: **what are the cons of Sublocade?** These range from injection site reactions to significant administration requirements [1.3.3, 1.4.2].